OncoMatch/Clinical Trials/NCT07137494
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Is NCT07137494 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MB-CART19.1 Cellular Therapy for primary central nervous system (cns) lymphoma.
Treatment: MB-CART19.1 Cellular Therapy — This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: methotrexate-based therapy — CNS-directed
All recurrent/refractory patients need to have received at least one prior CNS-directed methotrexate-based therapy
Cannot have received: CD19-targeted CAR T cell therapy
Exception: systemic lymphoma only
Prior treatment of systemic lymphoma with CD19-targeted CAR T cells
Cannot have received: chemotherapy
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
Cannot have received: monoclonal antibody
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
Cannot have received: targeted anticancer therapy
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
Cannot have received: nitrosourea
6 weeks for nitrosourea
Cannot have received: mitomycin-C (mitomycin-C)
6 weeks for ... mitomycin-C
Cannot have received: allogeneic hematopoietic stem cell transplantation
3 months since allogeneic hematopoietic stem cell transplantation
Cannot have received: immune checkpoint inhibitor
Patients exposed to immune checkpoint inhibitor within 8 weeks
Lab requirements
Kidney function
Creatinine Clearance ≥ 40 ml/min/m2
Liver function
direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN)
Cardiac function
LVEF <40% as assessed by most recent ECHO in the last 1 year excluded; NYHA stage III or IV congestive heart failure; myocardial infarction ≤6 months prior to enrollment; history of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
Creatinine Clearance ≥ 40 ml/min/m2, direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN); Impaired cardiac function (LVEF <40%) as assessed by most recent ECHO in the last 1 year; NYHA stage III or IV congestive heart failure; Myocardial infarction ≤6 months prior to enrollment; History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify